€¦ · Web viewAMH as predictor of premature ovarian insufficiency: A longitudinal study of 120...
Click here to load reader
-
Upload
truongduong -
Category
Documents
-
view
215 -
download
0
Transcript of €¦ · Web viewAMH as predictor of premature ovarian insufficiency: A longitudinal study of 120...
AMH as predictor of premature ovarian insufficiency:
A longitudinal study of 120 Turner Syndrome patients Stine Aa. Lunding1, Lise Aksglaede2, Richard A. Anderson3, Katharina M. Main4,5, Anders Juul4,5, Casper P.
Hagen4,5,6, Anette T. Pedersen1,5,6
1Department of Gynaecology / Fertility Clinic, Rigshospitalet, University of Copenhagen, Denmark2Department of Clinical Genetics, Rigshospitalet, University of Copenhagen, Denmark3Medical Research Council Centre for Reproductive Health, University of Edinburgh, United Kingdom4Department of Growth and Reproduction and EDMaRC, Rigshospitalet, University of Copenhagen,
Denmark5The Paed-Gyn Endo Transition Clinic at Rigshospitalet, University of Copenhagen, Denmark6These authors contributed equally to the supervision of this study
Abstract: 231
Word count: 3434
Tables: 1
Figures: 4
References: 42
Abbreviated Title: AMH as a predictor of POI in TS patients.
Key terms: Anti-Müllerian hormone, AMH, MIS, Turner Syndrome, premature ovarian insufficiency, POI,
POF, fertility, puberty.
Disclosure statement: The authors have nothing to disclose.
Corresponding author:
Stine Aagaard Lunding
University of Copenhagen
Fertility Clinic, Rigshospitalet
Blegdamsvej 9
DK-2100 Copenhagen O
Denmark
Email: [email protected]
1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
Abstract
Context: The majority of Turner syndrome (TS) patients suffer from accelerated loss of primordial follicles.
Low circulating levels of anti-Müllerian Hormone (AMH) may predict lack of spontaneous puberty in
prepubertal girls and imminent premature ovarian insufficiency (POI) in TS women with preserved ovarian
function.
Objectives: To evaluate the association between circulating AMH and ovarian status in TS patient.
Design: Longitudinal observational cohort study.
Setting: Tertiary referral centre for paediatric and gynaecologic endocrinology.
Participants: 120 Turner syndrome patients, aged 0 to 48 years.
Main outcome measures: Longitudinal measurements of AMH, FSH, LH, estradiol and inhibin B according
to age, karyotype (45,X; 45,X/46,XX mosaicism; miscellaneous karyotypes) and ovarian status (group 0:
prepubertal; group 1: never ovarian function; group 2: ongoing ovarian function; group 3: loss of ovarian
function).
Results: Ovarian status was highly associated with the TS karyotype; spontaneous puberty: 45,X (3/44
patients), 45,X/46,XX (15/17), miscellaneous (17/42) and POI: 45,X (3/3 patients), 45,X/46,XX (1/15),
miscellaneous (8/17). AMH was associated with ovarian status (e.g. group 1: < 2 pmol/L vs. group 2: 19
pmol/L, p<0.001). AMH < 4 pmol/L (corresponding to < -2SD) predicted absent puberty in prepubertal girls
and POI in adolescent and adult patients.
Conclusion: The majority of women with mosaic karyotype 45,X/46,XX had on-going ovarian function in
early adulthood. AMH < -2SD predicted failure to enter puberty in young TS girls and imminent POI in
adolescent and adult TS patients.
2
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
Introduction
Turner Syndrome (TS) affects 1/2000 new-born females (1,2). The syndrome is caused by X-chromosome
abnormalities with or without mosaicism and is characterized by an increased risk of primary or premature
ovarian insufficiency (POI) due to accelerated loss of germ cells before or after puberty (3–6).
Counselling TS patients about their reproductive function is challenging and depends on the age of the
patient. In prepubertal girls, the hypothalamic-pituitary-gonadal (HPG) axis is centrally inhibited, making the
biochemical assessment of ovarian activity difficult as circulating levels of reproductive hormones are
extremely low or undetectable (7). In adolescents and in adults, POI can be evaluated clinically and
biochemically with the classic combination of amenorrhea and elevated FSH concentrations
(hypergonadotropic hypogonadism) (8,9). However, in postpubertal adolescents and adult women,
reproductive hormones may remain within the normal range before POI is clinically evident, despite
significant depletion of the ovarian reserve (10–12). Very little is known about the timing and onset of POI
in TS patients with initially normal ovarian function, which makes it difficult to predict their fertility
prognosis.
The specific TS karyotype can to some degree predict the potential ovarian function in Turner patients, as
monosomic patients (45,X) usually are born with streak gonads, whereas those with 45,X/46,XX mosaicisms
have the best chance of spontaneous puberty and fertility (5,13,14). However, the karyotypes determined
from peripheral blood lymphocytes or skin biopsies lack specificity and sensitivity due to the unknown
degree of gonadal mosaicism (15).
In both prepubertal girls and adult women, anti-Müllerian hormone (AMH) is produced by small antral
follicles (16,17). In healthy adult women, circulating AMH reflects the number of primordial follicles (18)
and is therefore predictive of the reproductive lifespan (19–21). In girls and adolescents, AMH varies
markedly between individuals (reference ranging from 5 to 60 pmol/L), but overall each girl maintains her
AMH level through childhood and adolescence (22,23). In cross sectional studies, serum AMH is a sensitive
and specific marker of ovarian function in adolescent Turner syndrome patients (22,24,25).
3
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
In this longitudinal study of 120 Turner Syndrome patients, we aimed to assess the predictive value of AMH
for spontaneous puberty in prepubertal TS girls and imminent POI in adolescent and adult TS patients.
Material and Method
TS patients
All TS patients (n=137) identified by ICD-10 codes DQ96-DQ96.9 were recruited from the Department of
Gynaecology, the Department of Growth and Reproduction and the Paed-Gyn Endo Transition Clinic at
Rigshospitalet, University of Copenhagen, Denmark. Seventeen of 137 patients were excluded from the
study due to gonadectomy (n=7), age above 50 years (n=4), or lack of medical record information (n= 6),
leaving 120 patients for further evaluation.
Clinical and biochemical information were retrieved from patient files. Circulating AMH measurements
were available from 2009-2014 in a total of 101 TS patients (81 %). Longitudinal samples ( 2 samples)
were available in 73 patients (median 3 samples, range 2-13 per patient). Data from 71 patients including
longitudinal FSH, LH, inhibin B and estradiol and single measurement of AMH, have been reported
previously (7,22)
Karyotypes
Diagnosis of TS was confirmed by G-band karyotyping of blood lymphocytes, including counting of at least
10 metaphases, three of which were fully analysed. All karyotypes in the present study were validated by the
same clinician (LA). According to their karyotype, the TS patients were divided into three groups: 45,X (n=
48), 45,X/46,XX (n= 26) and miscellaneous without Y chromosome material (n= 46)
Ovarian status
Regardless of karyotype and AMH, the 101 TS patients with AMH measurements were categorized into four
ovarian function status groups, evaluated by pubertal breast stage (Tanner’s classification (26)), occurrence
of spontaneous menarche, menstrual bleeding pattern, serum levels of estradiol, FSH and LH, and hormone
replacement therapy (HRT):
4
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
Group 0. Prepubertal (n = 11): No spontaneous puberty (Tanner = 1) and age < 12 years. No HRT.
Group 1. Never ovarian function (n = 55): Age > 12 years and no spontaneous puberty. Puberty and
menarche induced by HRT.
Group 2. Ongoing ovarian function (n = 23): Spontaneous pubertal onset (Breast Tanner ≥ 2) and/or
spontaneous menarche and/or regular menstruation. No indications for HRT. Two patients with uterine
agenesis (both 45,X/46,XX) were categorized in this group as FSH, LH, inhibin B and estradiol were in the
reference range.
Group 3. Loss of ovarian function (n = 12): Spontaneous puberty and/or menarche followed by cessation of
pubertal development and/or secondary amenorrhea and hypergonadotropic hypogonadism. HRT indicated.
Hormone assays
Blood samples were taken as part of the clinical follow-up on the patients. The AMH assay has been
available for clinical use at Rigshospitalet, Copenhagen University Hospital since January 2009. All samples
were withdrawn from an antecubital vein, clotted, centrifuged and analysed. Serum AMH levels were
determined using the Beckman Coulter enzyme immunometric assay (IOT, Immunotech, Beckman Coulter
Ltd., Marseilles, France) with a detection limit of 2.0 pmol/l. The intra-assay coefficients of variation (CVs)
were less than 7.8% and 5.4% at 13 and 123 pmol/l, respectively. Inter-assay CV was less that 11.6% and
10.9% at 19 and 99 pmol/L, respectively.
The age specific reference range of AMH was based on serum samples from 926 healthy females aged 0-69
years (22).
Serum FSH and LH were measured by time-resolved immunofluorometric assays (Delfia; PerkinElmer,
Boston, MA) and by electrochemiluminescence immunoassays (Roche Diagnostics, Mannheim, Germany),
respectively .The detection limits from both assays were; FSH < 0.1 IU/L and LH < 0.1 IU/L. Intra-assay and
inter-assay CVs from both assays were < 5% for FSH and LH.
Between 1990 and 2010, serum inhibin B was measured using one of two double antibody enzyme
immunometric assays (Inhibin B DSL or Oxford Bio-Innovation Inhibin B), both with a detection limit of 20
pg/ml and intra- and interassay CV < 16%. From 2010, inhibin B was measured using the Beckman Coulter
5
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
Inhibin B genII assay, with a detection limit of 3 pg/ml and intra- and interassay CV < 11%. The old and
new inhibin B methods were compared extensively before changing assays, and showed similar results and
no correction factor was needed. Estradiol was measured by RIA (Pantex, Santa Monica, CA; before 1998
distributed by Immuno Diagnostic Systems, Bolton, UK) with a detection of 18 pmol/L, and intra- and
interassay CVs < 8% and <13%, respectively. Testosterone was measured by radioimmunoassay (RIA)
(Coat-a-count, Diagnostic Products, Los Angeles, CA) with a detection limit of 0.23 nmol/L and intra- and
interassay CV both < 10%.
Statistics
Pearson’s chi-squared test was used to assess if the prevalence of spontaneous puberty depended on
karyotype.
Differences in AMH levels between groups of TS patients (according to karyotype or ovarian status) were
assessed by Mann-Whitney U test (2 groups) and Kruskall Wallis test (3 groups). Each patient contributed
with a single AMH value, using the mean value if repeated measurements were available.
Intra-individual coefficients of variation (CV = SD /mean x 100%) were calculated.
To evaluate AMH as a predictor of spontaneous puberty, we described repeated AMH measurements from
15 patients prior to pubertal onset; spontaneous puberty (n=5) vs. HRT induced puberty (n=10). To evaluate
AMH as a predictor of POI, we used the last AMH measurement prior to POI in adolescents and adults who
later experienced loss of ovarian function. In addition, we visualized all individual AMH values before and
after POI. We further evaluated AMH as a marker of POI in patients > 12 years. Each patient contributed
with a single AMH value, using the mean value if repeated measurements were available. A receiver
operating characteristic (ROC) curve was established, providing the AMH cut-off with the best combination
of sensitivity and specificity. Patients were divided in two groups; A) POI: patients with “Never ovarian
function” (Group 1) or “Loss of ovarian function” (Group 3) using AMH values measured after onset of POI;
B) Ovarian function: patients with “Ongoing ovarian function” (Group 2).
The study was approved by The Danish Data Protection Agency (2014-41-2699).
6
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
Results
Description of the TS cohort
Descriptive characteristics of the TS cohort according to karyotypes and ovarian function are shown in Table
1. The prevalence of spontaneous puberty was significantly higher in patients with miscellaneous karyotypes
(17/42) than with karyotype 45,X (3/44) and highest in patients with 45,X/46,XX mosaicism (15/17), p <
0.001.
AMH levels and association with karyotype
45,X
AMH was measured in 39 out of 48 (81%) TS patients with karyotype 45,X (Figure 1A). twenty-seven of
these (69 %) had exclusively undetectable levels of AMH (average of 2 measurements, range 1 – 5). The
four prepubertal girls with 45,X had AMH levels below the normal reference range (max 2 pmol/L in all
samples)
45,X/46,XX mosaicism
AMH was measured in 21 out of 26 (80%) TS patients with 45,X/46,XX mosaicism (Figure 1B), median 16
pmol/L (< 2 – 92). Only three patients had undetectable AMH values. Three of the four prepubertal girls
with 45,X/46,XX had AMH levels within the reference range; median AMH 6 pmol/L (< 2 – 11).
Miscellaneous karyotypes
AMH was measured in 41 out of 46 (89%) TS patients with miscellaneous karyotypes (Figure 1C). Eight
patients (20 %) had AMH within the normal reference range; karyotypes; 45,X/46,XX/47,XXX (n = 2),
45,X/47,XX, 45,X/46,X,r(X), 46,X,del(X) (n =2), 45,X/46,X,del(X) (n = 2).
The three prepubertal girls with miscellaneous karyotypes had AMH levels below the reference range (max
2 pmol/L in all samples).
7
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
AMH was higher in TS patients with mosaicism (45,X/46,XX) compared with patients with 45,X (16 pmol/L
(<2 – 92) vs. <2 pmol/L (<2 – 2), p<0.001) Figure 1). In the majority of TS patients, AMH levels remained
relatively stable during follow up: i.e. the median intra-individual CV was 21% (0 – 172%).
Eight TS patients were taking oral contraceptives at the time of AMH measurements (marked with black dots
in figure 1).
AMH levels and association with ovarian status
There were 55 patients who never had any clinical signs of ovarian function (group 1) and all but three
patients had AMH levels below the reference range (Figure 2A). The three patients with a single AMH value
in the reference range had elevated FSH serum levels at 102, 69 and 42 IU/L, respectively.
Twenty-three out of 35 TS patients with spontaneous puberty had ongoing ovarian function (66%) (group 2)
during the study period (Figure 2B), and one TS patient conceived naturally (45,X/46,XX). The karyotype
distribution for the 23 patients with ongoing ovarian function was 45,X: 4%, 45,X/46,XX: 65% and
miscellaneous 31%. All but two of these 23 patients had AMH within the reference range; median 19 pmol/L
(<2 – 92) (Figure 2B). In 17/23 patients, AMH was stable or slightly increasing. AMH declined in the
remaining 5 patients; median (range) decline of AMH was 20 (3 – 79) pmol/L during a median time period
of 1.8 years (0.2 – 3.6).
AMH was markedly lower in women who never had ovarian function compared with women with ongoing
ovarian function; AMH < 2 pmol/L (range <2 – 8) vs. 19 pmol/L (range < 2 – 92), p<0.001 (Figure 2A vs.
2B).
AMH as a predictor of pubertal onset
AMH prior to pubertal onset was available in 15 patients. In 10 of these 15 patients puberty was induced
with HRT, and AMH was detectable in 3 of these 10 girls, median (range) < 2 (< 2 – 4) pmol/L. AMH was
detectable in 4 of the 5 girls who later had spontaneous pubertal development, mean of repeated individual
AMH measurements 4, 6, 20 and 58 pmol/L, respectively.
8
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
AMH as a predictor of POI
During follow up, 12 TS patients developed POI (group 3) (Figure 2C). Four of these patients lost ovarian
function after onset of spontaneous puberty but before menarche at a median age of 15.6 years (12.7 - 23.1),
while 8 patients had secondary amenorrhea at a median age of 19 years (15.2 – 32.9).
The karyotype distribution for these 12 patients was 25 % (3/12) 45,X, 8 % (1/12) 45,X/46,XX and 67 %
(8/12) miscellaneous karyotypes, respectively
AMH was measured in 5 of the 12 patients prior to cessation of pubertal development or secondary
amenorrhea (POI); median of last AMH value prior to POI: < 2 pmol/L (< 2 – 5) (Figure 3A).
Measurements of serum levels of FSH, LH, estradiol and inhibin B are shown only prior to onset of POI (and
hence prior to HRT) (Figure 3B – E). FSH, LH and estradiol levels prior to POI was 30.6 IU/L (5.86 – 93.7),
9 IU/L (0.5 – 47) and 20 pmol/L (< 18 – 54), respectively. Inhibin B was available in four patients prior to
POI; median < 20 pg/ml (< 20 – 55). Inhibin B decreased to undetectable levels within one year prior to POI
(Figure 3E).
AMH as a marker of POI
Based on the mean of individual AMH measurements from each adolescent and adult patient, the best cut-off
value for AMH as a marker of POI was 3 pmol/L. Both the sensitivity (probability of having POI when
AMH ≤ 3 pmol/L) and the specificity (probability of having ovarian function when AMH > 3 pmol/L) were
95 % (Supplementary Figure 1).
TS patients with high AMH
Seven TS patients had AMH > +2SD. Five of these patients had regular menstrual cycles, one patient
suffered from metrorrhagia and one was born with no uterus.
Ultrasound of the ovaries was described in 5 of the seven patients. Three of the patients had slightly enlarged
ovaries with up to 12 small follicles (< 9 mm diameter) per ovary, but morphology was not classically
PCOS-like with follicles located close to the ovarian cortex. Two patients had normal ovarian morphology.
Serum testosterone was measured in 5 of the 7 patients and found normal with a range from 0.02 to 1.9
9
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
nmol/L. Median (range) LH/FSH ratio was 1.34 (0.25 – 4.22). Pubic hair from the symphysis to the
umbilicus was described in one patient.
Discussion
This unique longitudinal cohort of 120 Turner syndrome patients in a transition setting from paediatrics to
gynaecology allowed us for the first time to evaluate AMH as a predictor of absent puberty and imminent
premature ovarian insufficiency (POI). No prepubertal girls with AMH < 4 pmol/L entered puberty
spontaneously, and in adolescents, AMH < 5 pmol/L (< -2SD) was indicative of imminent POI. ROC
analysis of cross sectional data from adolescent and adult patients confirms that low AMH is indicative of
POI (AMH ≤ 3 pmol/L was a sensitive (95%) and specific (95%) marker of POI). Our present ROC analysis
does not asses the diagnostic value of AMH to predict future POI in adult patients with ongoing ovarian
function, but suggests that, AMH is a valuable predictive tool when counselling prepubertal Turner
Syndrome patients as well as adolescents regarding remaining ovarian function and their future reproductive
lifespan.
Supporting previous studies, we observed that the TS karyotype was a strong predictor for spontaneous
pubertal onset and menarche (15,22,24,25). Due to a potential hidden grade of mosaicism, which is
frequently found in TS patients when analysing extended number of metaphases (27), the predictive value of
karyotypes for POI is poor (28,29).
A subset of TS patients – predominantly those with mosaicism 45,X/46,XX – had ongoing ovarian function
well into early adulthood. The majority of TS women with spontaneous menarche and continuous ovarian
function had stable AMH levels within the reference range during the 5 years of follow up. As in adult
women, AMH seems to reflect the number of small growing follicles in both healthy girls and Turner
Syndrome patients (17,25). Thus, as in healthy adult women, AMH in girls and in TS patients most likely
reflects the number of resting primordial follicles, thus determining the reproductive lifespan.
In our longitudinal analysis, AMH below the reference range was associated with absence of spontaneous
puberty onset in prepubertal girls as well as with imminent POI in adolescents and adults . To explore further
10
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
how AMH reflects ovarian function, we evaluated AMH as a marker (not a predictor) of POI in adolescent
and adult patients. This information is useful when interpreting AMH in prepubertal patients when the
central inhibition of the HPG axis prevents assessment of ovarian function with traditional reproductive
hormones (7). The highly sensitive and specific AMH cut-off (< 3 pmol/L) as a marker of POI in adolescent
TS patients supports that low AMH is reflecting compromised ovarian activity in prepubertal girls. Our
findings are in line with a large European Turner study reporting that the chance of spontaneous pubertal
onset was increased 19 times if AMH was detectable (24). This is also consistent with data from girls with
cancer treated with gonadotoxic chemotherapy and irradiation (30).
Compared with the AMH cut-off reported in a subgroup of TS patients from the present study (8 pmol/L)
(22), the new cut-off based on a larger number of patients is close to the detection limit of the AMH assay (2
pmol/L) and below -2SD. This is reassuring for normal girls with AMH in the low part of the reference
range, suggesting that they are not facing imminent POI. However, prospective studies are needed for
clarification.
Not all TS women with no ovarian function had undetectable AMH, and two patients even had single
measurements within the reference range. Thus, a limited number of small AMH producing follicles may be
present in patients who fulfil the criteria for the definition of POI. However, these small follicles may not
produce sufficient estradiol to initiate pubertal development (25).
When we evaluated other reproductive hormone levels as predictors of POI, particularly inhibin B appeared
to be of potential predictive value with levels dropping markedly during the year preceding POI, however,
data are sparse. In many of the patients, gonadotropins and estradiol were not affected before clinical
manifestation of POI. The finding of declining inhibin B is consistent with data indicating the predictive
value of inhibin B concerning the natural menopause (30,31). However, the predictive value of inhibin B is
hampered by its variation through the menstrual cycle, resulting in undetectable values in samples from some
healthy women during the luteal phase (33).
11
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
In experimental settings, cryopreservation of ovarian tissue is offered to TS girls and adolescents with the
potential chance of preserving remaining ovarian follicles. However, there are no reports of follicle survival
after thawing, and no pregnancies have yet been reported after auto-transplantation of tissue in this patient
group (34,35). Therefore, ovarian cryopreservation introduces a risk of loss of precious ovarian tissue that
may have maintained ovarian function including endogenous hormone production and potentially
spontaneous pregnancy. Ovarian stimulation, aspiration and vitrification of mature oocytes, is an alternative
method of fertility preservation, however, not always feasible in young TS patients. As AMH is a
quantitative rather than a qualitative marker of primordial follicles, i.e. low AMH is associated with early
menopause (19,21), it is not predictive of fecundability in young adult women (36). Thus, it is not yet
possible to determine, which patients will benefit from fertility preservation strategies. Our data indicate, that
potential candidates may be found among patients with 45,X/46XX mosaicism and miscellaneous karyotypes
with relatively preserved AMH levels.
We were puzzled by the few patients with high AMH values, similar to what is observed in PCOS patients
(37). The etiology of PCOS is still not elucidated, however, early exposure to androgens may predispose to
PCOS (38,39). Premature adrenarche and increased levels of DHEAS have been observed in TS girls (40).
However, only one TS patient in this study had polycystic ovarian morphology (> 12 follicles size 2-9 mm)
and none had clinical or biochemical hyperandrogenism. Thus it is highly speculative if TS patients with
remaining ovarian function have increased risk of developing PCOS.
A higher number of Turner patients with a longer clinical follow-up of absent spontaneous puberty or
secondary amenorrhea are required to conclude firmly on the predictive value of absolute AMH levels.
AMH measurements cannot be directly compared between commercially available assays, and reports of
different converting factors suggest that the assays have been modified continuously (41). Therefore, the
absolute AMH levels reported in this study should be used with caution for other AMH assays. Nevertheless,
the relative levels based on a well-defined reference range are clinically useful as AMH < -2SD is predictive
of absent pubertal onset (prepubertal patients) and imminent POI (adolescents and adults). The introduction
12
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
of more sensitive AMH assays may improve further the accuracy of interpretation of low AMH
concentrations. This has recently been demonstrated in the context of assessment of ovarian function after
chemotherapy for early breast cancer (42).
In conclusion, the majority of women with mosaic karyotype 45,X/46,XX had on-going ovarian function in
early adulthood and AMH levels within the reference range in early adulthood. AMH < -2SD predicted
failure to enter puberty in prepubertal TS girls and imminent POI in adolescent and adult TS patients. Longer
follow up is required to assess the value of AMH levels in predicting the reproductive lifespan in patients
with Turner syndrome.
References
1. Lespinasse J, Gicquel C, Robert M, Le Bouc Y. Phenotypic and genotypic variability in monozygotic triplets with Turner syndrome. Clini Genet. 1998;54(1):56–59.
2. Stochholm K, Juul S, Juel K, Naeraa RW, Gravholt CH. Prevalence, incidence, diagnostic delay, and mortality in Turner syndrome. J Clin Endocrinol Metab. 2006;91(10):3897–3902.
3. Turner HH. A syndrome of infantilism, congenital webbed neck, and cubitus valgus. Endocrinology, vol. 23, pp. 566-574, 1938. Endocrinol. 1938;23(5):566–574.
4. Sybert V, McCauley E. Turner’s syndrome. N Engl J Med. 2004:1227–1238.
5. Modi D, Sane S, Bhartiya D. Accelerated germ cell apoptosis in sex chromosome aneuploid fetal human gonads. Mol Hum Reprod. 2003;9(4):219–225.
6. Speed RM. Oocyte development in XO foetuses of man and mouse: the possible role of heterologous X-chromosome pairing in germ cell survival. Chromosoma. 1986;94(2):115–124.
7. Hagen CP, Main KM, Kjaergaard S, Juul A. FSH, LH, inhibin B and estradiol levels in Turner syndrome depend on age and karyotype: longitudinal study of 70 Turner girls with or without spontaneous puberty. Human Reprod. 2010;25(12):3134–3141.
8. Knauff E a H, Eijkemans MJC, Lambalk CB, ten Kate-Booij MJ, Hoek A, Beerendonk CCM, Laven JSE, Goverde AJ, Broekmans FJM, Themmen APN, de Jong FH, Fauser BCJM. Anti-Mullerian hormone, inhibin B, and antral follicle count in young women with ovarian failure. J Clin Endocrinol Metab. 2009;94(3):786–792.
9. Sahmay S, Usta T a, Erel T, Atakul N, Aydogan B. Elevated LH levels draw a stronger distinction than AMH in premature ovarian insufficiency. Climacteric. 2014;17(2):197–203.
13
330
331
332
333
334
335
336
337
338
339
340
341342
343344
345346
347
348349
350351
352353354
355356357358
359360
10. Van Rooij IAJ Van, Tonkelaar I Den, Broekmans FJM, Looman CWN, Scheffer GJ, Jong FH De, Themmen APN, Velde ER. Anti-müllerian hormone is a promising predictor for the occurrence of the menopausal transition. Menopause. 2004;11(6):601–606.
11. Fanchin R, Schonäuer L maria, Righini C, Guinourdenche J, Frydman R, Taieb J. Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Human Reprod. 2003;18(2):323–327.
12. Vet A De, Laven JSE, Ph D, Jong FH De, Themmen APN, Fauser BJCM. Antimüllerian hormone serum levels : a putative marker for ovarian aging. Fertil Steril. 2002;77(2):357–362.
13. Reynaud K, Cortvrindt R, Verlinde F, De Schepper J, Bourgain C, Smitz J. Number of ovarian follicles in human fetuses with the 45,X karyotype. Fertil Steril. 2004;81(4):1112–1119.
14. Hreinsson J, Otala M, Fridström M, Borgström B, Rasmussen C, Lundqvist M, Tuuri T, Simberg N, Mikkola M, Dunkel L, Hovatta O. Follicles are found in the ovaries of adolescent girls with Turner’s syndrome. J Clin Endocrinol Metab. 2002;87(March):3618–3623.
15. Pasquino A, Passeri F, Pucarelli I, Segni M, Municchi G. Spontaneous Pubertal Development in Turner’s Syndrome 1. J Clin Endocrinol Metab. 1997;82(6):1810–1813.
16. Jeppesen J V, Anderson RA, Kelsey TW, Christiansen SL, Kristensen SG, Jayaprakasan K, Raine-Fenning N, Campbell BK, Yding Andersen C. Which follicles make the most anti-Mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection. Mol Hum Reprod. 2013;19(8):519–527.
17. Hagen CP, Mouritsen A, Mieritz MG, Tingsgaard J, Wohlfart-Veje C, Fallentin E, Brocks V, Sundberg K, Jensen LN, Anderson RA JA, KM M. Circulating AMH reflects ovarian morphology by Magnetic Resonance Imaging and 3D-ultrasound in 121 healthy girls. Journal of Clinical Endocrinology and Metabolism. [Epub ahead of print] doi:10.1210/jc.2014-3336.
18. Hansen KR, Hodnett GM, Knowlton N, Craig LB. Correlation of ovarian reserve tests with histologically determined primordial follicle number. Fertil Steril. 2011;95(1):170–175.
19. Tehrani FR, Solaymani-Dodaran M, Tohidi M, Gohari MR, Azizi F. Modeling age at menopause using serum concentration of anti-mullerian hormone. J Clin Endocrinol Metab. 2013;98(2):729–735.
20. Broer SL, Broekmans FJM, Laven JSE, Fauser BCJM. Anti-Mullerian hormone: ovarian reserve testing and its potential clinical implications. Human Reprod Update. 2014;20(5):688–701.
21. Broer SL, Eijkemans MJC, Scheffer GJ, van Rooij I a J, de Vet A, Themmen a PN, Laven JSE, de Jong FH, Te Velde ER, Fauser BC, Broekmans FJM. Anti-mullerian hormone predicts menopause: a long-term follow-up study in normoovulatory women. J Clin Endocrinol Metab. 2011;96(8):2532–2539.
22. Hagen CP, Aksglaede L, Sørensen K, Main KM, Boas M, Cleemann L, Holm K, Gravholt CH, Andersson A-M, Pedersen AT, Petersen JH, Linneberg A, Kjaergaard S, Juul A. Serum levels of anti-Müllerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in 172 Turner syndrome patients. J Clin Endocrinol Metab. 2010;95(11):5003–5010.
23. Hagen CP, Aksglaede L, Sørensen K, Mouritsen A, Andersson A-M, Petersen JH, Main KM, Juul A. Individual serum levels of anti-Müllerian hormone in healthy girls persist through childhood and adolescence: a longitudinal cohort study. Hum Reprod. 2012;27(3):861–866.
14
361362363
364365366
367368
369370
371372373
374375
376377378379
380381382383
384385
386387
388389
390391392393
394395396397
398399400
24. Visser JA, Hokken-Koelega ACS, Zandwijken GRJ, Limacher A, Ranke MB, Flück CE. Anti-Müllerian hormone levels in girls and adolescents with Turner syndrome are related to karyotype, pubertal development and growth hormone treatment. Hum Reprod. 2013;28(7):1899–1907.
25. Borgström B, Hreinsson J, Rasmussen C, Sheikhi M, Fried G, Keros V, Fridström M, Hovatta O. Fertility preservation in girls with turner syndrome: prognostic signs of the presence of ovarian follicles. J Clin Endocrinol Metab. 2009;94(1):74–80.
26. Marshall W a., Tanner JM. Variations in the Pattern of Pubertal Changes in Girls. Arch Dis Child. 1969;44:291–303.
27. Hook EB, Warburton D. Turner syndrome revisited: review of new data supports the hypothesis that all viable 45,X cases are cryptic mosaics with a rescue cell line, implying an origin by mitotic loss. Hum Genet. 2014;133(4):417–424.
28. Fernández‐García R, García-Doval S, Costoya S, Pásaro E. Analysis of sex chromosome aneuploidy in 41 patients with Turner syndrome: a study of “hidden”mosaicism. Clin Genet. 2000;(5):201–208.
29. Held KR, Kerber S, Kaminsky E, Singh S, Goetz P, Seemanova E, Goedde HW. Mosaicism in 45,X Turner syndrome: does survival in early pregnancy depend on the presence of two sex chromosomes? Hum Genet. 1992;88(3):288–294.
30. Brougham MFH, Crofton PM, Johnson EJ, Evans N, Anderson R a, Wallace WHB. Anti-Müllerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study. J Clin Endocrinol Metab. 2012;97(6):2059–2067.
31. Sowers MR, Eyvazzadeh AD, McConnell D, Yosef M, Jannausch ML, Zhang D, Harlow S, Randolph JF. Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J Clin Endocrinol Metab. 2008;93(9):3478–3483.
32. Overlie I, Mørkrid L, Andersson A-M, Skakkebaek NE, Moen MH, Holte A. Inhibin A and B as markers of menopause: a five-year prospective longitudinal study of hormonal changes during the menopausal transition. Acta Obstet Gynecol Scand. 2005;84(3):281–285.
33. Sehested A, Juul AA, Andersson AM, Petersen JH, Jensen TK, Müller J, Skakkebaek NE. Serum inhibin A and inhibin B in healthy prepubertal, pubertal, and adolescent girls and adult women: relation to age, stage of puberty, menstrual cycle, follicle-stimulating hormone, luteinizing hormone, and estradiol levels. J Clin Endocrinol Metab. 2000;85(4):1634–1640.
34. Huang J, Tulandi T, Holzer H, Lau N, MacDonald S, Tan S, Chian R-C. Cryopreservation of ovarian tissue and in vitro matured oocytes in a female with mosaic Turner syndrome: Case Report. Hum Reprod. 2008;23(2):336–339.
35. Oktay K, Cil AP, Zhang J. Who is the best candidate for oocyte cryopreservation research? Fertil Steril. 2010;93(1):13–15.
36. Hagen CP, Vestergaard S, Juul A, Skakkebæk NE, Andersson A-M, Main KM, Hjøllund NH, Ernst E, Bonde JP, Anderson R a, Jensen TK. Low concentration of circulating antimüllerian hormone is not predictive of reduced fecundability in young healthy women: a prospective cohort study. Fertil Steril. 2012;98(6):1602–1608.
15
401402403
404405406
407408
409410411
412413414
415416417
418419420
421422423
424425426
427428429430
431432433
434435
436437438439
37. Dewailly D, Gronier H, Poncelet E, Robin G, Leroy M, Pigny P, Duhamel A, Catteau-Jonard S. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod. 2011;26(11):3123–3129.
38. Franks S. Polycystic ovary syndrome in adolescents. Int J Obes. 2008;32(7):1035–1041.
39. Abbott DH, Dumesic DA, Franks S. Developmental origin of polycystic ovary syndrome - a hypothesis. J Endocrinol. 2002;174(1):1–5.
40. Martin DD, Schweizer R, Schwarze CP, Elmlinger MW, Ranke MB, Binder G. The early dehydroepiandrosterone sulfate rise of adrenarche and the delay of pubarche indicate primary ovarian failure in Turner syndrome. J Clin Endocrinol Metab. 2004;89(3):1164–1168.
41. Kumar A, Kalra B, Patel A, McDavid L, Roudebush WE. Development of a second generation anti-Müllerian hormone (AMH) ELISA. J Immunol Methods. 2010;362(1-2):51–59.
42. Chai J, Howie AF, Cameron DA, Anderson RA. A highly-sensitive anti-Müllerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancer. Eur J Cancer. 2014;50(14):2367–2374.
16
440441442443
444
445446
447448449
450451
452453454
455
456
457
458
459
460
461
462
463
464
Table 1. Descriptive characteristics of the Turner syndrome patients according to karyotype and ovarian status (n = 117). In those with
45,X/46,XX three patients were not included in the table; two women had uterus agenesis and in one woman information on ovarian status
was missing.
17
465
466
467
468
469
Figure Legends
Figure 1
Serum AMH levels in girls, adolescents and women with Turner syndrome according to age and karyotypes;
45,X (A), 45,X/46,XX (B) and miscellaneous karyotypes (C). Red: prepubertal girls; Green: patients with
ongoing ovarian function; Black: hormonal contraceptive treatment at the time of AMH measurement; Grey:
patients with no ovarian function. Note the logarithmic Y-scale. Blue lines indicate the reference range
(median, 2.5th and 97.5th percentile) based on 926 samples from healthy Danish infants, girls, adolescents and
adults (22).
Figure 2
Serum AMH levels in girls, adolescents and women with Turner syndrome according to age, reference range
and their ovarian status: never ovarian function (A), ongoing ovarian function (B), and loss of ovarian
function (C). Green: patients with ongoing ovarian function. Grey/black: patients with no ovarian function.
Note the logarithmic Y-scale. Blue lines indicate the reference range (median, 2.5 th and 97.5th percentile)
based on 926 samples from healthy Danish infants, girls, adolescents and adults (22).
Figure 3
Serum AMH levels (A) in women with Turner syndrome before and after POI, the 12 women are represented
by different colours. FSH (B), LH (C), estradiol (D) and inhibin B (E) levels in women with Turner
syndrome in the years preceding development of POI or initiation of HRT (red line). The blue line represents
the 2.5th percentile corresponding to -2SD of the reference range. The blue dotted line represents the
detection limit of 2 pmol/L.
Supplementary Figure 1
18
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
Receiver operative characteristic (ROC) curve visualizing a high sensitivity and specificity for AMH as a
marker of POI in adolescent TS patients.
19
495
496
497